Latest news

• Novo Nordisk growth takes a hit with China deal

  Ryzodeg contains a combination of long acting insulin degludec – which Novo markets as Tresiba – and rapid-acting insulin aspart, while Novo sells as NovoRapid. ... The assumption from Novo’s announcement is that Tresibo and NovoRapid, as well as

• Novo follows Sanofi, Lilly with insulin price cut in US

  The Danish drugmaker says it will offer an authorised generic version of NovoLog (insulin aspart) at around $145 per vial, roughly half the branded drug’s current US list price, from ... which offered a 50% cheaper version of its Humalog (insulin lispro

• Novo Nordisk preps for speedy oral GLP-1 drug filing

  10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone. ... Novo’s CEO Lars Fruergaard Jørgensen. New fast-acting mealtime insulin Fiasp (insulin aspart),

• Gilead's hepatitis B virus treatment set for European approval

  The dual-therapy works to reduce high blood glucose while enhancing glucose-dependent insulin secretion and reducing glucagon release. ... Meanwhile, Novo Nordisk looks set to add Fiasp (insulin aspart) to its diabetes drug stable, as the fast-acting

• Novo Nordisk's Tresiba gaining ground in basal insulin market

  Sales of Novo Nordisk's new basal insulin product Tresiba have started to gather momentum since its US launch in January, rising three-fold in the first half of the year. ... Nevertheless, the strong sales performance for Tresiba and other new insulin